argenx SE

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
ARGXargenx SE -0.78%373.830.0%$100.58m
VRXValeant Pharmaceuticals International, Inc. 2.15%6.9014.1%$40.60m
BRBRBellRing Brands, Inc. -1.61%23.910.0%$25.82m
RVMDRevolution Medicines, Inc. 0.05%21.870.0%$15.95m
USNAUSANA Health Sciences, Inc. -0.60%52.954.2%$3.47m
PRPHProPhase Labs, Inc. -0.78%10.200.1%$0.97m
CDXCChromadex Corp. 0.00%1.702.4%$0.61m
QLGNQualigen Therapeutics, Inc. 2.22%1.840.0%$0.35m
BVXVBiondVax Pharmaceuticals Ltd. -16.51%7.770.0%$0.35m
NATRNature's Sunshine Products, Inc. 0.11%9.010.4%$0.33m
IMCCIM Cannabis Corp. -5.42%2.270.0%$0.32m
UPXIUpexi, Inc. 4.08%4.080.0%$0.31m
FLGCFlora Growth Corp. 6.43%0.500.0%$0.26m
BGXXBright Green Corp. 2.20%0.570.0%$0.25m
PMCBPharmaCyte Biotech, Inc. -1.30%3.030.0%$0.19m

Company Profile

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.